Gantenerumab
Beta-amyloid (Aβ40/42) | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6496H10072N1740O2024S42 |
Molar mass | 146276.71 g·mol−1 |
(what is this?) (verify) |
Gantenerumab is a
Gantenerumab binds to and clears aggregated
beta amyloid fibers.[3]
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.[6]
References
- ^ "Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.
- S2CID 4795458.
- PMID 29221491.
- ^ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
- ^ Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.